Data Insights

Tafasitamab by Incyte for Hematological Tumor: Likelihood of Approval

Tafasitamab is under clinical development by Incyte and currently in Phase II for Hematological Tumor. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Tafasitamab in Hematological Tumor

Data Insights

Tafasitamab by Incyte for Primary CNS Lymphoma: Likelihood of Approval

Tafasitamab is under clinical development by Incyte and currently in Phase II for Primary CNS Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Tafasitamab in Primary CNS Lymphoma

Data Insights

Tafasitamab by Incyte for Leukemia: Likelihood of Approval

Tafasitamab is under clinical development by Incyte and currently in Phase II for Leukemia. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Tafasitamab in Leukemia

Data Insights

Tafasitamab by Incyte for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Tafasitamab is under clinical development by Incyte and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Tafasitamab in Chronic Lymphocytic Leukemia (CLL)

Data Insights

Tafasitamab by Incyte for Marginal Zone B-cell Lymphoma: Likelihood of Approval

Tafasitamab is under clinical development by Incyte and currently in Phase III for Marginal Zone B-cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Tafasitamab in Marginal Zone B-cell Lymphoma

Data Insights

Tafasitamab by Incyte for Precursor B-Cell Lymphoblastic Leukemia-Lymphoma: Likelihood of Approval

Tafasitamab is under clinical development by Incyte and currently in Phase II for Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Tafasitamab in Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Data Insights

Tafasitamab by Incyte for Non-Hodgkin Lymphoma: Likelihood of Approval

Tafasitamab is under clinical development by Incyte and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Tafasitamab in Non-Hodgkin Lymphoma

Data Insights

Tafasitamab by MorphoSys for Primary CNS Lymphoma: Likelihood of Approval

Tafasitamab is under clinical development by MorphoSys and currently in Phase II for Primary CNS Lymphoma. According to GlobalData, Phase...

Data Insights

Tafasitamab by MorphoSys for Leukemia: Likelihood of Approval

Tafasitamab is under clinical development by MorphoSys and currently in Phase II for Leukemia. According to GlobalData, Phase II drugs...